lobbying_activities: 1229429

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1229429	2db75f22-fb21-418f-8e2d-515eaa20363a	Q1	CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.	8511	ONYX PHARMACEUTICALS	2012	first_quarter	MED	Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; No Bill #: Prescription Drug User Fee Act reauthorization	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE	30000		0	0	2012-04-17T13:10:42.267000-04:00